We’ve rebranded some of our products, learn more ›
Webinar | Mar 8, 2023 | 8AM PT | 11AM ET | 5PM CET
Immune checkpoint inhibitors have proven an effective treatment for mucosal head and neck squamous cell cancer (HNSCC). With the success of anti-PD-1/PD-L1 immune checkpoint inhibitor therapy among human papillomavirus-positive and negative patients, we must now focus on developing a consistently predictive biomarker to guide patient selection for highly targeted checkpoint inhibitor therapies.
This webinar will discuss how single-cell multiomic spatial phenotyping is an invaluable tool to characterize the tumor microenvironment using unbiased whole-slide imaging of metastatic/recurrent HNSCC tumors among patients treated with pembrolizumab/nivolumab. Using these techniques, we were able to identify stromal, immune, and metabolic tissue signatures associated with resistance to immunotherapy and poor overall survival.
Key learning objectives:
Arutha Kulasinghe is a Peter Doherty NHMRC Research Fellow and leads the 'Clinical-oMx Lab' at the University of Queensland. Kulasinghe has pioneered spatial transcriptomics using digital spatial profiling approaches in the Asia-Pacific region, contributing to world-first studies for lung cancer, head and neck cancer, and COVID-19. His research aims to understand the underlying pathobiology by using an integrative multi-omics approach. Kulasinghe has published his research in 60 manuscripts and is supported by the NHMRC, the Australian Academy of Sciences, Cancer Australia, Cure Cancer, MRFF, and numerous philanthropic and hospital foundations.
Sign up to receive our eNewsletter, new product updates, events, and more!